The revenue for Setrusumab is expected to reach an annual total of $133 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Setrusumab Overview

Setrusumab is under development for the treatment of osteogenesis imperfecta type I, III and IV (also known as Brittle bone syndrome). The drug candidate is administered intravenously through infusion. It is a fully humanized monoclonal antibody targeting sclerostin. It was also under development for hypophosphatasia (HPP), osteoporosis in postmenopausal women and chronic kidney disease.

Mereo Biopharma Group Overview

Mereo Biopharma Group is a specialty bio-pharmaceutical company. The company develops novel medicines for the treatment of rare and specialty diseases. It’s pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome and BCT-197, and Etigilimab (MPH-313), which treats solid tumors. Mereo Biopharma Group also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotropic hypogonadism and its Navicixizumab (OMP-305B83) is in Phase 1 clinical trial which treats platinum-resistant ovarian cancer. The company collaborates with biotechnology and pharmaceutical companies. Mereo Biopharma Group is headquartered in London, England, the UK.

The operating loss of the company was GBP43.6 million in FY2022, compared to an operating loss of GBP20.9 million in FY2021. The net loss of the company was GBP34.2 million in FY2022, compared to a net profit of GBP12.7 million in FY2021.

For a complete picture of Setrusumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.